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Abstract: Human papillomaviruses (HPV) have now been identified as a necessary cause of benign and malignant lesions 
of the differentiating epithelium, particularly cervical cancer, the second most prevalent cancer in women worldwide. 
While two prophylactic HPV vaccines and screening programs are available, there is currently no antiviral drug for the 
treatment of HPV infections and associated diseases. The recent progress toward the identification and characterization of 
specific molecular targets for small molecule-based approaches provides prospect for the development of effective HPV 
antiviral compounds. Traditionally, antiviral therapies target viral enzymes. HPV encode for few proteins, however, and 
rely extensively on the infected cell for completion of their life cycle. This article will review the functions of the viral E1 
helicase, which encodes the only enzymatic function of the virus, of the E2 regulatory protein, and of the viral E6 and E7 
oncogenes in viral replication and pathogenesis. Particular emphasis will be placed on the recent progress made towards 
the development of novel small molecule inhibitors that specifically target and inhibit the functions of these viral proteins, 
as well as their interactions with other viral and/or cellular proteins. 
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HPV INFECTION AND ASSOCIATED DISEASES 
  Human papillomaviruses (HPV) are small, double-
stranded DNA viruses that induce benign and malignant 
hyperproliferative lesions of the differentiating epithelium of 
the skin and mucosa. To date, more than 150 different HPV 
types have been identified [1, 2], including approximately 30 
to 40 types that preferentially infect the mucosa of the 
anogenital tract, causing a variety of abnormalities ranging 
from genital warts to invasive cancer. Of these, infection by 
oncogenic or high-risk HPV types such as HPV16,-18,-31, 
-33 or -45 is implicated in the development of cervical 
cancer [3], one of the most common cancers among women 
worldwide, as well as other genital malignancies and a 
subset of head-and-neck cancers [4, 5]. Given that HPV 
DNA is detected in more than 99% of cancerous cervical 
lesions [6], high-risk HPV strains are now well established 
as the causative agents for the development of cervical 
cancer [7] and many anal cancers [8, 9]. HPV16 is the most 
prevalent, accounting for over 50% of cancerous lesions and 
their precursors [10, 11]. Other low-risk HPV types such as 
HPV6 and -11 are also associated with specific pathological
 
conditions including anogenital condyloma or benign genital 
warts [12], as well as recurrent laryngeal papillomatosis [13]. 
More recently, studies have also suggested the involvement 
of cutaneous HPV types in a subset of non-melanoma skin 
cancers [14]. 
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  Although HPV infection is quite common, the majority 
of these infections clear spontaneously with time. However, 
in some cases the infection will persist, a known risk factor 
for progression to malignancy. While carcinogenesis does 
not occur in the majority of infected individuals, cervical 
cancer is still the second leading cause of cancer-related 
deaths in women worldwide. There are an estimated 493,000 
new cases of cervical cancer that result in 233,000 deaths per 
year worldwide [15]. Annually, an estimated 11,070 women 
are diagnosed with invasive cervical cancer in the United 
States alone, and about 4000 women die from this disease 
[16]. Although not life-threatening, genital warts are also 
very common with approximately 1 million new cases 
diagnosed each year in the United States [10]. The burden of 
HPV infections is greater in developing countries and 
accounts for approximately 83% of all new cases due to a 
lack of adequate screening programs [17]. Despite the high 
incidence of HPV infection and its associated malignant 
diseases, there is currently no effective antiviral agent 
available for therapy. Current therapeutic approaches are 
usually aimed at the removal of HPV lesions through 
surgical excision or cryotherapy, making them mostly 
invasive and cytodestructive in nature [18, 19]. A limited 
number of non-surgical treatments have been clinically 
approved including topical applications of imiquimod or 
podophyllin for treatment of genital warts [20, 21]. 
However, due to viral persistence and the limited efficacy of 
such non-specific treatments, rates of recurrence are high, 
especially for patients with immunologic deficiencies. The 
development of prophylactic HPV vaccines represents a 
major advance for the prevention of human cancers. In June 
2006, the US FDA approved Gardasil
® developed by Merck 
and Co. Inc. as the first HPV vaccine. This quadrivalent 
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vaccine is based on recombinant virus-like particles (VLP) 
from HPV6,-11,-16, and -18 and has been shown to be 
highly effective in preventing pre-cancerous cervical lesions 
and genital warts caused by these HPV types [22]. A second 
HPV vaccine, Cervarix
TM developed by GlaxoSmithKline 
has recently received FDA approval [23]. This vaccine is a 
bivalent VLP vaccine directed against the high-risk viruses 
HPV16 and -18 [10]. Both vaccines seem to be effective in 
blocking infections against the most prevalent HPV types 
and are expected to significantly reduce persistent HPV 
infection and the incidence of cervical abnormalities in 
regions where vaccination rates are high [24]. These 
vaccines have also been recently approved for use in men for 
the prevention of HPV-associated penile cancers and 
possibly for the prevention of oral cancers associated with 
high-risk HPV types [25]. They do not, however, offer 
protection against all HPV types, nor are they of therapeutic 
value in already infected patients. In fact, up to 30% of 
cervical cancers are caused by HPV types not covered by 
current vaccines [26], emphasizing the need for the 
development of novel and effective therapy in combating the 
progression of HPV-associated diseases. This article reviews 
the recent progress made toward the development of such 
novel antiviral agents for the treatment of HPV infections, 
with emphasis on the identification of small molecule 
inhibitors that specifically target and inhibit essential HPV 
protein functions and viral-host protein interactions. 
THE HPV LIFE CYCLE 
  Precise knowledge of the different stages of the viral life 
cycle of HPV has been well described and serves as a 
molecular basis for the development and evaluation of 
antiviral compounds for the treatment of HPV infections. 
Productive HPV infection is dependent upon the cellular 
differentiation program that keratinocytes undergo in the 
epithelium. HPV virions initially infect cells in the basal 
layer of the epithelium where their viral double-stranded 
DNA genome are maintained as autonomously replicating 
extrachromosomal elements (i.e., episomes) in the nucleus of 
infected cells (reviewed in [27, 28]). Following entry into 
basal epithelial cells, the virus takes advantage of the cellular 
replication machinery to allow for low levels of viral DNA 
synthesis, resulting in an episomal copy number of 
approximately 50-100 genomes per cell. Upon 
differentiation of infected cells, productive replication is 
established such that the viral genome is amplified to more 
than 1000 copies and expression of capsid proteins is 
induced, resulting in the synthesis of infectious virions that 
are assembled and released. The fact that efficient replication 
of the HPV episome relies on host cell factors that are 
expressed in S-phase, and thus not normally synthesized in 
differentiating post-mitotic keratinocytes, represents a 
particular challenge to the virus. To circumvent this problem, 
HPVs have developed a process mediated primarily by the 
viral gene products E6 and E7 to induce infected cells to 
enter S-phase while maintaining their differentiated state. 
The primary mean by which the viral oncogenes E6 and E7 
exert this effect on the cell cycle of infected cells is by 
abrogating the p53 and retinoblastoma (Rb) tumor 
suppressor pathways, respectively. This cooperation between 
the two viral oncoproteins promotes a cellular environment 
supporting viral DNA replication by stimulating infected 
differentiating keratinocytes to re-enter S-phase (E7), while 
preventing p53-dependent cell cycle arrest and apoptotic 
response (E6) [27]. 
  Genomic organization is a well conserved feature among 
papillomaviruses. The HPV genome, approximately 8 Kb in 
size, contains three main regions, the early and late regions, 
based on the timing of viral protein expression following 
viral entry into the host cell, and the long control region 
(LCR). The early region encodes predominately for 
regulatory proteins that are essential for viral transcription 
and replication, as well as cell cycle control, contributing to 
the transformation and immortalization potential of HPV. 
The late region encodes for the two viral structural proteins, 
L1 and L2, needed for capsid formation. The LCR contains 
most of the regulatory DNA sequences needed for 
replication of the viral genome and for expression of the 
viral genes, including the origin of DNA replication and 
enhancer and promoter regions, respectively [27]. In total, 
the HPV genome encodes eight well characterized proteins 
(Fig. 1). 
E1 AND E2 PROTEINS AS ANTIVIRAL TARGETS 
  Viral replication and gene expression by the E1 and E2 
proteins are obvious functions that could be targeted by 
small molecules for therapeutic intervention of HPV-
associated diseases. Together with the cellular replication 
machinery, replication of the HPV genome requires the viral 
helicase E1 and the origin-binding protein E2. Structure-
function studies have shown that E1 contains three 
functional domains: a C-terminal ATPase/helicase domain 
capable of oligomerization into hexamers [29, 30], a central 
origin DNA-binding domain (OBD) [31], and an N-terminal 
regulatory region that is essential for replication in vivo but 
dispensable in vitro [32]. More specifically, this N-terminal 
region contains conserved sequences for nuclear localization 
(NLS), nuclear export (NES), a conserved cyclin-binding 
motif (CBM) that interacts with cyclin A/E-Cdk2 [33, 34], as 
well as several phosphorylation sites for this kinase and 
others [33, 35, 36] (Fig. 2A). As such, E1 functions both as a 
DNA binding protein to recognize the viral origin and as a 
helicase to unwind DNA ahead of the replication fork. Given 
its key role in HPV replication and the fact that it is the only 
enzymatic gene product encoded by the virus, E1 is 
undoubtedly an attractive target for the development of novel 
therapeutic agents. E2 is also considered a valid candidate 
target for antiviral compounds aimed at blocking viral DNA 
replication. E2 is a multifunctional protein that specifically 
binds to sites in the regulatory region of the viral genome to 
promote viral DNA replication, regulate viral gene 
transcription, and govern proper segregation of the viral 
episome to daughter cells at mitosis [37-41]. The E2 protein 
is organized into two functional domains: an N-terminal 
transactivation domain (TAD) that is involved in 
transcriptional regulation and direct association with E1, and 
a C-terminal DNA-binding/dimerization domain (DBD). 
Both these domains are separated by a hinge region that is 
thought to be flexible and whose function has been poorly 
characterized (Fig. 2A). Recruitment of E1 to the origin is 
facilitated by its interaction with E2 [42-49], which binds to 
sites in the viral origin with high affinity (reviewed in [50]). 
Through these interactions, E2 not only facilitates 
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in the assembly of additional E1 proteins into replication-
competent double hexamers necessary for bidirectional DNA 
unwinding. Through interactions with E1, cellular replication 
factors such as DNA polymerase -primase [51-53], 
topoisomerase I [54], and the single-stranded DNA binding 
protein RPA [55, 56] are recruited to the origin for assembly 
into an active replication complex (Fig. 2B). As such, both 
E1 and E2 are absolutely necessary for viral DNA replication 
in vivo [57]. Reverse genetic experiments have shown that 
both these viral proteins are essential for the maintenance of 
the viral episome in primary human keratinocyte cultures 
[45] and for pathogenesis in the cottontail rabbit 
papillomavirus (CRPV) infection model [58]. 
  In addition to its role in replication, E2 is also implicated 
in the regulation of viral gene transcription and segregation 
of the episome at mitosis [37, 39]. Depending on the 
promoter context, E2 has either activating or repressing 
functions. For instance, E2 activates transcription from a 
minimal promoter under the control of multimerized E2-
binding sites [59], while in the context of the viral genome, 
E2 represses viral transcription driven from the LCR during 
the early stages of viral infection, particularly of the E6 and 
E7 genes [59-63]. Given its role as a transcriptional 
regulator, E2 has been shown to associate with a number of 
cellular transcription factors including TFIIB [64-66], TBP 
and TFIID [64, 67-69], AMF-1/GPS2 [70], p300/CBP [71, 
72], NAP-1 [73], P/CAF [74], and TopBP1 [75]. More 
recent studies have demonstrated that the bromodomain-
containing protein 4 (Brd4), a chromatin associated factor, is 
crucial for both the transactivation and repression functions 
of E2 [76-78]. As a segregation factor, E2 tethers the viral 
episome to mitotic chromatin [39, 79-81] and possibly also 
to the mitotic spindle [82, 83]. Biochemical assays have 
identified Brd4 as the E2 interacting protein responsible for 
chromosome tethering [40, 76, 78, 84-87]. The possibility   
 
that all papillomavirus types rely on Brd4 for segregation or 
that alternative mechanisms exist is currently a subject of 
intense studies [88-90]. Mutational analyses of the E2 TAD 
have revealed that substitutions at amino acids arginine 37 
and isoleucine 73 specifically abrogate binding to Brd4. 
These mutations inhibit the transcriptional activity of E2 but 
have little effect on its ability to support replication and 
maintenance of the viral episome in HPV immortalized 
keratinocyte cultures, and to complete the viral life cycle in 
organotypic raft cultures [76, 77, 86]. In contrast, similar 
mutations in CRPV E2 were found to completely abolish the 
ability of the cloned CRPV genome to induce epithelial 
tumors in rabbits [91], suggesting an essential role for the 
interaction of E2 with Brd4 in viral pathogenesis. 
  Overall, it is clear that both the E1 and E2 proteins 
represent valid targets for therapeutic intervention. Given 
that these proteins are relatively well conserved in sequence 
and in function suggests that the use of small molecule-based 
approaches to interfere with the helicase/ATPase activity of 
E1, the E1-E2 interaction, or even the binding of E2 to Brd4 
should be effective for the treatment of infections caused by 
different HPV types. 
E1 ATPASE INHIBITORS 
  HPV lack the enzymes generally targeted by currently 
available antiviral agents, such as proteases and polymerases. 
E1 is the only enzymatic gene product with ATPase and 
DNA helicase activities that facilitate unwinding of the viral 
DNA ahead of the replication fork. Inhibition of this 
unwinding activity, powered mainly by the hydrolysis of 
ATP [92], would essentially block viral replication. 
Furthermore, since ATP promotes the oligomerization of E1 
into hexamers, which in turn affects the interaction of E1 
with E2, ATP can be viewed as an allosteric modulator of 
the E1-E2 protein interaction. The ATPase and unwinding   
 
 
Fig. (1). Genomic organization of the HPV genome. Schematic representation of the HPV16 circular genome showing the location of the 
early (E) and late genes (L1 and L2), and of the long control region (LCR). The HPV genome encodes eight well-characterized proteins, 
whose functions are indicated. Among them are the viral replication proteins E1 and E2 (violet) and the viral oncogenes E6 and E7 (green), 
all of which have been validated as essential for viral pathogenesis and represent genuine targets for small molecule-based approaches for the 
treatment of HPV-associated diseases. Small Molecule Inhibitors of HPV Protein Interactions  The Open Virology Journal, 2011, Volume 5    83 
 
activities are located within the C-terminal region of E1, the 
same region that binds to E2. Studies have shown that E2 
binding hinders the ATPase activity of E1 and similarly, that 
ATP weakens the E1-E2 interaction and impairs the 
cooperative binding of E1 and E2 to the origin [30]. These 
findings led to the proposal that ATP, in addition to 
powering the helicase activity of E1, also acts as a molecular 
trigger during the initiation of viral DNA replication to help 
weaken the E1-E2 interaction and promote E1 
hexamerization at the origin [30, 47]. As such, interfering 
with ATP binding and/or ATPase activity would result in the 
inhibition of HPV DNA replication and would be a valid 
strategy for the development of HPV antivirals. Small 
molecule inhibitors targeting the ATPase activity of HPV6 
E1 have been identified by high-throughput screening of a 
large compound collection of greater than 500,000 diverse 
 
Fig. (2). Initiation of HPV DNA replication. (A) Schematic representation of the viral proteins E1 and E2 required for replication of the 
HPV genome. E1 and E2 are approximately 650 and 370 amino acids in length, respectively. Locations of the different functional domains in 
each protein are indicated. OBD: origin binding domain; TAD: transactivation domain; H: hinge region; DBD: DNA-binding domain. (B) 
Schematic diagram of the initiation of HPV DNA replication. (I) Replication is initiated by the recruitment of E1 (blue), by E2 (yellow), to 
the viral origin. This recruitment step involves an essential protein-protein interaction between the TAD of E2 and the helicase domain of E1 
that can be antagonized by the Indandione or Repaglinide class of small molecule inhibitors. (II) E2 recruits additional E1 molecules and 
promotes their assembly into a replication-competent double hexameric helicase. ATP also stimulates the oligomerization of E1 and is 
further needed to power the helicase activity of E1. Biphenylsulfonacetic acid inhibitors have been identified that abrogate the ATPase and 
helicase activities of E1. (III) Finally, E1 interacts with host cell replication factors such as polymerase  primase (pol ; orange) to promote 
bidirectional replication of the viral genome. 84    The Open Virology Journal, 2011, Volume 5  D’Abramo and Archambault 
chemical entities [93]. Lead molecules consisted of 
biphenylsulfonacetic acid analogues characterized by the 
presence of a biphenyl group substituted with a 
sulfonylacetic acid moiety [93] (Fig. 3A). Kinetic studies 
revealed that the mode of action of these compounds is 
characteristic of a hyperbolic competitive mechanism, 
suggesting that they do not bind directly at the ATP-binding 
site, but affect ATP binding through an allosteric mechanism 
[94]. Thus, the activity of these inhibitors is a function of the 
ATP concentration. Given that the biphenyl and 
sulfonylacetic acid moieties were determined to be important 
for potency, both pharmacophores were subjected to 
chemical modifications for the synthesis of derivatives with 
improved potency, with IC50 values as low as 4 nM (Fig. 
3A). Of interest was the finding that the addition of 
substituted amides at the 3’ and 4’ positions of the biphenyl 
moiety significantly improved the affinity of the original 
lead inhibitor for HPV6 E1 [93]. These modifications, 
however, only slightly improved the affinity of these 
compounds for the related HPV11 E1 protein. In fact, they 
were 2- to 10-fold less active against the ATPase activity of 
HPV11 E1 compared to that of HPV6 E1. Given the high 
level of conservation between the helicase domains of these 
two proteins, a series of mutagenesis studies were conducted 
to identify amino acids within E1 important for inhibition 
[94]. This led to the identification of Tyr-486, which is a 
cysteine in HPV11, as the single critical residue in HPV6 E1 
responsible for inhibitor potency and binding. This was 
further substantiated by the finding that substitution of Cys-
486 for tyrosine in HPV11 E1 substantially increased its 
sensitivity to the inhibitors. Interestingly, HPV18 E1 also 
contains a tyrosine at this position and accordingly could be 
inhibited by this class of inhibitors, although at a reduced 
potency compared to HPV6 E1. This latter finding raises the 
possibility that this class of small molecule inhibitors could 
be optimized for activity against many HPV types [94]. 
Using the crystal structure of the HPV18 E1 helicase domain 
as a tool to determine the possible binding region of these 
inhibitors revealed that Tyr-486 in HPV6 E1 is located close 
to the highly conserved Lys-484, an essential residue for 
ATP interaction and catalysis [95] (Fig. 3B,  C). It has 
therefore been speculated that the interaction of these 
inhibitors with Tyr-486 may induce a conformational change 
in E1 that would indirectly affect ATP binding, accounting 
for their allosteric mode of action. Consistent with the fact 
that ATP hydrolysis is required for helicase activity, the 
inhibitors also inhibited the helicase activity of HPV6 E1 in 
vitro. Despite these promising results, the biphenyl-
sulfonacetic acid inhibitors were not active in cell-based 
assays [93], perhaps attributable in part to the relatively high 
intracellular concentration of ATP. Nonetheless, this class of 
inhibitors has demonstrated the potential of the E1 ATPase 
domain as a target for inhibition of HPV DNA replication by 
small molecules. The identification of the small molecule 
binding pocket on the HPV E1 protein by X-ray crystallo-
graphy of an E1-inhibitor complex would be the next logical 
step towards the design of second generation inhibitors with 
increased specificity and activity. 
 
 
 
E1-E2 INTERACTION INHIBITORS 
  To date, relatively few small molecule inhibitors of 
protein-protein interactions have been identified. A potential 
explanation for this is that small molecules may have 
difficulty in competing against the large surface area 
typically involved in a protein-protein interface, which 
furthermore, tend to be fairly flat and devoid of small 
molecule binding pockets. Nevertheless, several studies have 
demonstrated that substitution of a single critical residue at 
an interface is sufficient to greatly weaken an interaction 
[96], thereby raising the possibility that some protein 
interfaces might be amenable to small molecule inhibition. 
For HPV, one such protein-protein interaction target includes 
the binding between E1 and E2. Viral DNA replication is 
initiated by the recruitment of E1, by E2, to specific DNA 
sequences within the viral origin of replication. Formation of 
a ternary complex between E1, E2, and the origin facilitates 
recognition of the viral origin by E1 and serves as a platform 
for the recruitment of additional E1 molecules and their 
assembly into replication-competent double hexamers 
capable of bidirectional unwinding [29, 97, 98]. Assembly of 
this E1-E2-ori ternary complex is dependent upon the 
interaction of E1 and E2 with DNA, and upon a critical 
protein interaction between the TAD of E2 and the C-
terminal ATPase domain of E1 [42-44, 46-49]. A priori, any 
of the protein-protein or protein-DNA interactions that take 
place at the origin can be targeted for the development of 
small molecule inhibitors for the treatment of HPV lesions. 
To date, substantial efforts have been made toward the 
discovery of compounds that specifically target and inhibit 
the DNA-binding activities of E1 and E2 or prevent the E1-
E2 interaction, with only a few studies demonstrating 
efficacy  in vivo. A class of small molecules termed 
indandiones, which specifically inhibit the E1-E2 protein 
interaction, have been identified as the first small molecule 
inhibitors of HPV DNA replication [99, 100]. The original 
inhibitor in this class of compounds was identified by high-
throughput screening of over 100,000 diverse chemical 
compounds for its ability to interfere with the cooperative 
binding of recombinant HPV11 E1 and E2 to radiolabeled 
origin DNA. Medicinal chemistry efforts then led to the 
synthesis of more active analogs capable of inhibiting the 
assembly of the HPV11 E1-E2-origin DNA complex with 
low nanomolar potency in vitro and with activity in cell-
based assays [100] (Fig. 4A). This set of inhibitors featured 
an indandione system spirofused onto a substituted 
tetrahydrofuran ring and was determined to act by binding to 
the TAD domain of E2, the same region of the protein that 
interacts with E1. Crystal structures of the HPV11 E2 TAD 
alone and in complex with an indandione inhibitor provided 
a detailed understanding of the mechanism by which the 
indandione inhibitors bind to E2 to disrupt the E1-E2 
interaction [101] (Fig. 4B, C ). Comparison of the two 
structures revealed that inhibitor binding did not 
significantly alter the protein backbone but did induce 
significant movement of several amino acid side chains at 
the binding site. These changes in side chain conformation, 
particularly of residues Tyr-19, His-32, Leu-94, and Glu- 
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Fig. (3). Inhibition of E1 ATPase activity. (A) Structures of the lead and optimized biphenylsulfonacetic acid inhibitors of the E1 ATPase 
activity with IC50 values of 2.0M and 4.0nM, respectively. (B) Crystal structure of the hexameric C-terminal helicase domain of bovine 
papillomavirus (BPV) E1 (PDB accession number 2GXA [173]). (C) Enlarged views of the ATP-binding pocket displaying the locations of 
the highly conserved catalytic Lys-439 (yellow), essential for ATP interaction and catalysis, and Met-441, (blue) important for the activity of 
biphenylsulfonacetic acid inhibitors. These residues are equivalent to Lys-484 and Tyr-486, respectively, in HPV6 E1. Bound ADP (red) is 
depicted in stick representation. 86    The Open Virology Journal, 2011, Volume 5  D’Abramo and Archambault 
100, resulted in the formation of a deep hydrophobic pocket 
that tightly binds to the indandione moiety of the inhibitor. 
The structure also revealed that the carboxylate moiety of the 
inhibitor, known to be important for potency, forms 
hydrogen bonds with amides from the protein backbone. 
These inhibitors were determined to bind specifically to the 
E2 protein of the two most prevalent low-risk HPV types, 
HPV6 and -11, rather than the high-risk types [100]. This 
lack of inhibition of high-risk E2 was attributable in part to 
residue His-32, which is a tyrosine in the E2 of most high-
risk HPV types. Substitution of His-32 for tyrosine in 
HPV11 E2 was found to abrogate inhibitor binding, although 
it did not affect interaction with E1. In fact, mutational 
analysis of several residues in or near the inhibitor binding 
pocket provided functional evidence for specific interactions 
between Tyr-19 and E1, and between His-32 and the 
inhibitor [101]. Substitution of His-32 is predicted to prevent 
the formation of the deep hydrophobic inhibitor binding 
pocket. Other subtle conformational changes may also 
explain why the indandione class of inhibitors bind to HPV6 
E2 less tightly than to HPV11 E2. Notably, mutation of Glu-
100 to alanine in HPV11 E2 was also determined to increase 
the sensitivity of E2 to the indandione inhibitors by 10-fold 
in vitro [102]. A subsequent screen also led to the discovery 
and optimization of a second series of reversible E1-E2 
interaction inhibitors (Fig. 4A). Modeling studies suggested 
that these repaglinide-derived inhibitors form weaker 
interactions with the E2 TAD but occupy a larger portion of 
the inhibitor binding pocket compared to the indandione 
series. The fact that potent repaglinide derivatives, with IC50 
values in the nanomolar range against HPV6 and HPV11 E2, 
could be obtained after only a few rounds of optimization 
makes this series a promising avenue for the development of 
small molecule inhibitors of the E1-E2 interaction [103]. Of 
interest is the finding that E1 and E2 interact through a 
relatively large surface area of approximately 950 Å
2, which 
includes the inhibitor binding pocket [95]. Thus, the 
indandione and repaglinide-derived inhibitors provide 
tangible examples that small molecules can indeed inhibit 
relatively large protein-protein interfaces. 
  The ability of the indandione compounds to inhibit HPV 
genome replication in vivo, especially that of low-risk HPV 
types, demonstrates for the first time the therapeutic 
potential of the E2 protein as a target for the development of 
small molecule inhibitors of HPV protein interactions, 
particularly in this case for the treatment of anogenital warts 
caused by HPV6 and -11. More specifically, the localization 
and characterization of this inhibitor binding pocket in the 
E2 TAD provides a potential new therapeutic target for the 
treatment of HPV infections. These studies have laid the 
foundation for the use of structure-based approaches to 
rationally design or virtually screen inhibitory compounds 
that are capable of binding to all or part of this identified 
inhibitor binding pocket. An understanding of such 
associations will aid in the design of additional small 
molecules that will exhibit improved biological effects and 
favorable associations with the E2 proteins of a wider range 
of HPV types. Given that the E1-E2 interaction is highly 
conserved between mucosal and cutaneous viruses, it is 
possible that antiviral compounds that antagonize this 
interaction would be effective against infections caused by 
many different HPV types. 
  While inhibition of E1 and/or E2 function represents a 
valuable strategy for the treatment of HPV-associated benign 
lesions such as warts, in which the viral genome is 
maintained as an episome, it is important to realize that 
expression of these two viral proteins is often lost during the 
process of malignant transformation. Integration of the viral 
DNA into the host genome and the concomitant loss of the 
E2 protein is a well-established risk factor for cancer 
development, as it often results in increased expression of 
the E6 and E7 oncogenes, albeit not invariably [104]. Since 
both E6 and E7 were shown to be essential for the 
proliferation and survival of cervical carcinoma cells, they 
are in principle the targets of choice for the treatment of 
HPV-induced cancers. 
TARGETING THE E6 AND E7 ONCOPROTEINS 
  The molecular functions of the HPV E6 and E7 
oncoproteins involved in cellular transformation and 
immortalization represent validated targets for therapeutic 
intervention. Both are small, zinc finger-containing proteins 
that need to be continually expressed for progression and 
maintenance of HPV-positive cancers. As mentioned above, 
expression of E6 and E7 is transcriptionally regulated by E2 
during the normal viral life cycle. In cancer progression, 
however, integration of the viral genome frequently occurs, 
often in a manner that disrupts the E2 open reading frame 
and eliminates the E2-mediated transcriptional control of the 
early region. This results in constitutive and/or increased 
overexpression of E6 and E7 in HPV-associated cancers 
[104]. Both E6 and E7 allow for the efficient 
immortalization of infected keratinocytes and thereby play 
an important role in HPV-induced carcinogenesis. In fact, 
cell culture and animal model studies have clearly 
established that expression of E6 and E7 from high-risk HPV 
types is necessary and sufficient to immortalize primary 
keratinocytes [105, 106], induce epithelial cell hyperplasia 
[107, 108], abrogate DNA damage responses [109, 110], and 
induce genomic instability [111, 112]. The oncogenic 
potential of these proteins is mediated by specific 
interactions with key cell cycle regulatory proteins, namely 
those of E6 with the tumor suppressor protein p53, and of E7 
with the retinoblastoma (Rb) family of pocket proteins. One 
important function of p53 is to transactivate the expression 
of various regulators that induce cell cycle arrest in G1/S 
and/or apoptosis in response to DNA damage, while that of 
Rb and the related pocket proteins p107 and p130 is to 
control the transition at the G1/S phase of the cell cycle by 
binding and regulating the activity of the E2F family of 
transcription factors. Consequently, through these 
interactions, E7 stimulates quiescent cells to re-enter S-
phase, while E6 prevents cellular growth arrest or DNA 
damage-induced apoptosis [27] (Fig. 5A). In support of this, 
studies have shown that an increase in cell proliferation was 
observed when the HPV16 E7 gene was expressed in the 
lens of transgenic mice or in the basal epithelial cells of the 
mouse epidermis [113, 114]. In other studies, repression of 
E6 and/or E7 expression in cervical carcinoma cell lines, by 
transfection of a functional E2 or by siRNAs, restored the 
p53 and Rb pathways and induced cellular senescence [105, 
115-119]. Moreover, it has been suggested that both E6 and 
E7 utilize the ubiquitin-proteosome system to target these 
cellular proteins for degradation and inactivation [120, 121]. Small Molecule Inhibitors of HPV Protein Interactions  The Open Virology Journal, 2011, Volume 5    87 
This has been first demonstrated for E6, which associates 
with the cellular E3 ubiquitin ligase E6-associated protein 
(E6AP), forming an E6/E6AP complex capable of binding 
p53 and inducing its specific ubiquitination and subsequent 
degradation by the proteasome [122]. Notably, the E6 
protein of low-risk HPV types does not induce p53 
degradation correlating with their weak transformation 
potential. HPV31 viral genomes containing mutations in E6 
that reduce E6AP binding or prevent p53 interaction were 
incapable of stable episomal maintenance and 
immortalization of primary keratinocytes [123]. Similar 
results were obtained with HPV31 viral genomes containing 
mutant E7 genes [123]. Together, these and other findings  
 
(reviewed in [27]) suggest that preventing the p53 
degradation function of E6 or the interaction between E7 and 
Rb and related pocket proteins represent promising avenues 
for the discovery of small molecule inhibitors of HPV-
induced carcinogenesis. 
  In addition to p53 and Rb, E6 and E7 have also been 
shown to interact with many other cellular proteins (recently 
reviewed in [124]). For instance, high-risk HPV E6 proteins 
containing the C-terminal sequence X-T/S-X-V/L interact 
with the PDZ-domain containing proteins hDlg, MUPP1, 
hScribble, MAGI-1-3, and PTPN13 targeting them for 
proteasome-mediated degradation [125-130]. These cellular  
 
 
 
Fig. (4). Inhibition of the E1-E2 protein interaction. (A) Structures and potencies of optimized indandione and repaglinide inhibitors of 
the E1-E2 protein-protein interaction. (B) Surface and ribbon representation of the HPV11 E2 TAD-indandione inhibitor complex (PDB 
accession number 1R6K [101]). The structure of the inhibitor used for crystallography is shown in (A). The amino acid residues that form the 
hydrophobic inhibitor-binding pocket are depicted in stick representation and are colored according to the legend in the figure. (C) Enlarged 
view of the hydrophobic pocket in the absence (left panel) and presence (right panel) of inhibitor, displaying the significant movement of the 
amino acids Tyr-19, His-32, Leu-94, and Glu-100 upon inhibitor binding. 88    The Open Virology Journal, 2011, Volume 5  D’Abramo and Archambault 
 
 
Fig. (5). Inhibition of the E6-E6AP interaction. ( A) Simplified model of how the HPV oncogenes E6 and E7 stimulate cellular 
proliferation. Binding of E7 to pRb leads to the release and activation of the E2F transcription factors and drives differentiating keratinocytes 
into S-phase. This unscheduled DNA synthesis triggers a p53-dependent cell cycle arrest and apoptotic response that is prevented by E6, 
through its interaction with E6AP, and targets p53 for proteasomal degradation. (B) Schematic representation of E6AP. E6AP possesses 
several well-characterized functional domains including a HECT domain (yellow) and an E6-binding site (E6BS). The amino acid sequence 
corresponding to the E6BS is indicated and the three conserved leucine residues, Leu-9, Leu-12, Leu-13, are highlighted in orange. (C) NMR 
structure of the E6AP peptide showing the positions of the three leucine residues, Leu-9, Leu-12, and Leu-13 important for E6 binding are 
colored in orange (PDB accession number 1EQX [152]). (D) Structure of Compound 9, an E6-E6AP inhibitor used as a starting point for the 
synthesis of other closely related inhibitors of E6 activity. Small Molecule Inhibitors of HPV Protein Interactions  The Open Virology Journal, 2011, Volume 5    89 
proteins, many of which are tumor suppressors [125, 131, 
132], function as structural organizers of signaling molecules 
in diverse cellular compartments to modulate cell polarity, 
cell-cell adhesion, ion transport, and normal cell growth. E6 
mediates the degradation of PDZ-domain proteins through 
both E6AP-dependent and E6AP-independent mechanisms 
[133-135]. This degradation results in the disruption of 
multiple signaling pathways and has been shown to be 
necessary for cell transformation [136], suggesting that 
abrogation of PDZ-domain containing proteins contributes to 
the oncogenic potential of E6. Studies of transgenic mice 
provide further support for this notion by demonstrating that 
an increase in cellular proliferation and induction of 
epithelial hyperplasia in the mouse lens and in the epidermis 
is dependent upon the binding of E6 to PDZ-domain proteins 
[137, 138]. Interfering with these processes could ultimately 
be a valuable approach for the development of specific HPV 
antiviral compounds. In fact, the efficacy of this approach 
has been shown by the use of synthetic peptides which 
efficiently abolished the ability of E6 to promote the 
degradation of the PDZ-domain proteins hDlg and MAGI-1 
in vitro [139]. In addition to its interaction with the Rb 
family of proteins, increasing evidence suggests that E7 
influences E2F-induced transcription through interactions 
with several other cellular proteins including the class I 
histone deacetylases (HDAC) [140, 141]. HDAC activity has 
been associated with cancer and to date, several HDAC 
inhibitors are in clinical trials [142]. The significance of the 
interaction between E7 and HDAC was demonstrated in 
reverse genetic experiments, where HPV31 genomes 
containing mutations in the E7 HDAC binding sequences 
were severely impaired in mediating episomal maintenance 
and in modulating cellular proliferation of primary 
keratinocytes [143]. These results validate this protein 
interaction as a potential antiviral target. Despite being 
attractive molecular targets from a biological standpoint, E6 
and E7 have historically proven to be refractory to inhibition 
by small molecules, perhaps because of their small size 
and/or lack of inhibitor binding pockets on their surface. 
Nevertheless, some important progress was recently reported 
toward the development of E6 inhibitors and is summarized 
below. 
E6-E6AP INHIBITORS 
  A key mechanism utilized by papillomaviruses to prevent 
apoptosis of infected cells involves the degradation of the 
tumor suppressor protein p53 by E6, in association with the 
cellular ubiquitin ligase E6AP, thereby also contributing to 
the immortalization abilities of high-risk HPV E6 proteins. 
Although all HPV E6 proteins have been shown to bind to 
p53 [144], degradation of p53 is specific to high-risk HPV 
types and relies upon the interaction between E6 and E6AP 
[145]. It has been demonstrated that downregulation of 
E6AP expression by antisense olignucleotides [146] or RNA 
interference [147], or inhibition of E6AP by dominant 
negative mutant proteins [148] resulted in accumulation of 
p53 protein levels and growth suppression in HPV-positive 
but not HPV-negative cells. Together, E6 and E6AP bind 
within the core DNA-binding domain of p53 and facilitate its 
ubiquitination and proteasomal degradation. The essential 
role of the E6/E6AP complex in the degradation of p53 is 
further supported by studies which demonstrated that mutant 
p53 proteins unable to bind E6 were not susceptible to 
E6AP-mediated degradation [149], while E6AP mutants 
defective for E6 binding were unable to interact with p53 
[150]. As such, inhibition of the E6-E6AP complex 
represents an attractive therapeutic target, as it would 
ultimately re-activate p53 function in high-risk HPV-positive 
cells leading to growth arrest and apoptosis of HPV-
transformed cells. 
  Different approaches have been tested to design effective 
inhibitors of the E6-E6AP complex. The starting point of one 
approach was the identification, by sequence alignment of 
several E6 interacting proteins, including E6AP, E6BP, 
paxillin, and interferon-regulatory factor 3 (IRF3), of a 
consensus E6-binding motif, L-x-x--L-s-h, where L is 
leucine, xx is a dipeptide in which one of the residues is 
aspartate, asparagine, glutamine, or glutamate,  is a 
hydrophobic residue (usually leucine), s is a small amino 
acid (glycine or alanine), and h is usually aspartate, 
asparagine, glutamine, or glutamate [151]. This motif folds 
into an -helix, such that the three leucine residues form a 
hydrophobic surface on one side of the helix and the charged 
amino acids lie on the opposite side. Mutagenesis studies 
revealed the critical importance of the three leucine residues 
(Leu-9, Leu-12 and Leu-13) for E6 binding [152]. 
Substitution of any leucine with alanine in the binding motif 
was shown to abolish binding to E6, whereas mutations of 
polar residues on the opposite side of the helix were shown 
to weaken binding. These features led to the suggestion that 
E6AP interacts with E6 through a “charged leucine” binding 
motif [151, 152] (Fig. 5B). As such, two small stable 
peptides were designed, where the minimal E6-binding 
consensus sequence was grafted into the single -helix of the 
third zinc-finger of Sp1 and the Trp-cage peptide [153]. 
Unfortunately, these peptides were only weak competitors of 
the interaction between E6-E6AP in comparison with the 18-
mer peptide from E6AP (residues 391 to 408) that 
encompasses the complete E6-binding motif and inhibits 
binding of E6AP to HPV16 E6 with an IC50 of 10 M in 
vitro [139, 153]. Structure of this 18-mer peptide lead was 
obtained by NMR [152] and is shown in Fig. (5C). Based on 
these structural and functional studies of E6-binding 
proteins, Baleja et al. [151] constructed an E6-binding 
pharmacophore model which they then used to identify 
potential inhibitory molecules by virtual screening of the 
National Cancer Institute (NCI) chemical database 
(approximately 240,  000 compounds) and Sigma Aldrich 
chemical database (97,  000 compounds). 73 candidate 
compounds were identified, which were further tested in 
vitro using a p53 degradation assay and a gel-based E6-
E6AP binding assay. Selectivity and cell permeability were 
also tested. 5 lead candidates were identified, which 
displayed acceptable selectivity and inhibitory activity (IC50 
values ranging between 17 μM-29  μM), however, no 
structure-activity relationship could be established from this 
limited dataset. Overall, these compounds, especially 
Compound 9, provide an exciting starting point for the 
synthesis of future inhibitors with improved potency and 
specificity (Fig. 5D). Future studies aimed at determining the 
structure of HPV E6-inhibitor complexes will ultimately 
increase our current understanding of how these compounds 
interact with E6 and will facilitate the identification of a 
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interface has been mapped, although it has been suggested 
that the binding pocket for E6AP lies at the junction of both 
zinc-binding domains [151]. The reported three-dimensional 
structural analysis of the C-terminal zinc-finger domain of 
HPV16 E6 provides a tool to assist with these studies [154]. 
The identification of small synthetic peptides that 
specifically bind to and inhibit the oncogenic activity of E6 
may also provide valuable information defining critical 
amino acid residues and contact points [155]. Overall, the 
fact that E6AP appears to be the primary protein needed for 
the E6-mediated degradation of p53, PDZ-domain 
containing proteins, and possibly other host proteins, 
strengthens the idea that obstruction of the E6AP-binding 
pocket on E6 is an attractive strategy for the development of 
small molecule inhibitors against HPV-induced 
pathogenesis. 
CONCLUSIONS 
  Modulating protein-protein interactions is becoming an 
increasingly attractive strategy for the development of small 
molecule inhibitors, but remains a challenge due to various 
obstacles such as lack of well-defined binding pockets and 
the need to compete with large protein-protein binding 
interfaces, etc. Nevertheless, reports on the discovery of 
inhibitors with nanomolar affinities and high specificities for 
their targets are increasing, demonstrating the feasibility of 
this approach for the treatment of diseases. Tremendous 
progress has been made in increasing our knowledge of the 
function of many of the viral proteins involved in the HPV 
life cycle. Among these proteins are E1, E2, E6, and E7, all 
of which have been validated as essential for viral 
pathogenesis and thus represent genuine targets for small 
molecule-based approaches for the treatment of HPV-
associated diseases. As shown above, small molecules that 
inhibit specific functions of these viral proteins are now 
emerging and have provided pharmacological validation that 
these viral targets are druggable. In particular, two protein-
protein interactions have been validated as HPV targets by 
small molecule inhibitors, namely the E1-E2 interaction and 
the E6-E6AP interaction. The use of small molecule-based 
approaches to interfere with the binding of E2 to Brd4 also 
represents an unexplored target for the treatment of HPV 
infections. Targeting this interaction is substantiated by a 
study reporting the development of a peptide that consists of 
the last 20 amino acids of Brd4 that is able to interact with 
E2 and specifically interfere with its ability to tether the viral 
DNA to chromatin [156]. Another yet unexplored target is 
the interaction between E6 and PDZ-domain containing 
proteins. PDZ domains have well-defined binding sites, 
making them promising targets for drug discovery. 
Additional studies clarifying the function of these domains in 
normal and infected cells, however, are necessary before 
PDZ interactions can be targeted for drug development. 
Alternatively, the development of small molecules that target 
p53 and protect it from E6-mediated degradation, rather than 
inhibit E6 directly, represents a promising novel strategy for 
the treatment of HPV-associated cancers. The recent 
identification of the small molecule inhibitor RITA serves as 
an example. RITA was determined to efficiently suppress the 
growth of cervical cancer cells both in vitro and in vivo. The 
molecule was found to target p53 directly and prevent its 
interaction with E6AP to protect it from proteasomal E6-
mediated degradation in both HPV16- and HPV18-infected 
cells [157]. The recent screening of a chemical library of 
compounds also identified two small molecules that 
selectively caused growth suppression of cervical cancer 
cells. Although not clearly established, inhibition of p53 
interaction with E6 or E6AP is considered as a possible 
mechanism of action [158]. Importantly, the identification of 
small peptides that bind to E6 and interfere with the E6-
mediated degradation of p53 or with other additional tumor 
relevant E6 interactions may also serve as a starting point for 
the development of small molecule peptide mimetics against 
HPV infection [155]. Finally, viruses have been shown in 
recent years to alter cellular physiology by modulating the 
expression of small noncoding regulatory RNAs or 
microRNAs (miRNAs or miR) [159, 160]. Although HPV 
does not encode miRNAs, it has been shown to affect host 
miRNA which could provide alternative avenues for the 
development of nucleic acid-based therapeutics. For 
instance, the viral E6 protein has been shown to promote 
cellular proliferation by reducing the expression of the tumor 
suppressor miR-34a [161] and to promote cell migration by 
downregulation of miR-23b, a p53 target gene [162]. 
Additionally, the viral E7 protein targets miR-203 to prevent 
the downregulation of the p63 family of transcription factors 
in order to promote viral genome amplification in 
differentiated keratinocytes [163]. However, several issues 
such as stability, delivery, and off-target effects of miRNAs 
remain to be addressed to realize their potential as antiviral 
agents. 
  For most of the existing HPV inhibitors, the weak 
antiviral effects observed in cellular assays suggest that 
further improvements in potency and cell penetration are 
required. However, it should be noted that all of the HPV 
inhibitors described in this review have been identified using 
biochemical assays or surrogate cell-based assays, such that 
their true antiviral activity is not known. While the use of in 
vitro assays facilitates the identification of active HPV 
compounds, it would be of great importance to determine 
their efficacy in more biologically relevant cellular or animal 
models of viral pathogenesis. For instance, the use of 
organotypic raft cultures of keratinocytes immortalized with 
high-risk HPV genomes is capable of reproducing the 
complete HPV life cycle leading to virion production, 
thereby allowing for a detailed mechanistic study of all 
stages of the viral life cycle [164-167]. Although there are no 
definitive animal models that are predictive of the efficacy of 
HPV antiviral inhibitors in humans, animal models of HPV 
carcinogenesis exist [168]. E6/E7 transgenic mice, for 
instance, can be used to evaluate inhibitors that affect the 
functions of high-risk E6 and E7, with the caveat that 
another ligase other than E6AP may be involved in 
mediating some of the activities of E6 in mice [134, 169]. 
The CRPV infection model, which has been used extensively 
for pre-clinical studies of vaccine efficacy [170-172], could 
also be used provided that the compounds are active against 
the CRPV proteins. Although demonstrating activity in an 
animal model of HPV pathogenesis would be of great value 
for the development of antivirals, it should not be regarded 
as essential given the limitations of existing models in 
mimicking the disease in humans. 
  The success of these inhibitors will also greatly depend 
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of the prevalent HPV types, with the ultimate hope that a 
pan-HPV inhibitor can be identified. It is also anticipated 
that basic research on the HPV life cycle will lead to the 
identification and validation of novel viral-host proteins 
interactions that can be exploited for the discovery of 
inhibitors capable of blocking critical stages of the viral life 
cycle. As the HPV genome is replicated by cellular DNA 
polymerases with high fidelity, the emergence of drug-
resistant viruses is not expected to be an issue. Thus, 
treatment with a single antiviral agent (i.e., monotherapy) 
should, in principle, be sufficient. However, in a clinical 
setting, it may be beneficial to simultaneously target 
different steps of the viral life cycle or to combine an 
antiviral compound with an immuno-stimulatory approach to 
achieve a more effective treatment of HPV infection. It is 
hoped that the studies presented above will provide an 
impetus for the development of better inhibitors and 
ultimately lead to the discovery of the first HPV antiviral 
drug capable of alleviating the burden of HPV infections, 
notably cervical cancer. 
ABBREVIATIONS 
Brd4  =  Bromodomain-containing protein 4 
CRPV  =  Cottontail rabbit papillomavirus 
CBM =  Cyclin-binding  motif 
DBD =  DNA-binding/dimerization  domain 
E6AP  =  E3 ubiquitin ligase E6-associated protein 
FDA  =  Food and Drug Association 
HDAC  =  Class I histone deacetylases 
HPV =  Human  papillomaviruses 
IRF3  =  Interferon-regulatory factor 3 
LCR  =  Long control region 
NES =  Nuclear  export  signal 
NLS =  Nuclear  localization  signal 
OBD  =  Origin DNA-binding domain 
Rb =  Retinoblastoma 
SPA  =  Scintillation proximity assay 
TAD =  Transactivation  domain 
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